Pulmonary hypertension is a life-threatening complication of sickle cell disease. L-arginine is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis. This deficiency may play a role in pulmonary hypertension. The enzyme arginase hydrolyzes arginine to ornithine and urea, and thus it may compete with nitric oxide synthase, leading to decreased nitric oxide production. Nitric oxide therapy by inhalation has improved pulmonary hypertension associated with acute chest syndrome in sickle cell disease, and several studies demonstrate therapeutic benefits of arginine therapy for primary and secondary pulmonary hypertension. We sought to determine the effects of arginine therapy on pulmonary hypertension in patients with sickle cell disease. Arginase activity was also determined. Oral arginine produced a 15.2 % mean reduction in estimated pulmonary artery systolic pressure (63.9±13 to 54.2±12 mmHg, p=0.002) after five days of therapy in ten patients.
INTRODUCTION
Pulmonary hypertension is a life threatening complication of sickle cell disease (1) , that has been reported to occur in up to 30% of adult patients (1, 2) . With improved medical care and a longer life expectancy, the number of affected patients will likely increase with time. The etiology of sickle cell disease-related pulmonary hypertension is unclear, treatment options are limited, and the prognosis is poor (3) . Patients who develop this complication have a shortened survival period (4) . Its presence is an independent predictor of death, with an average time to death after diagnosis being as short as 12 months (2) . Anecdotal treatments with vasodilators, oxygen, anticoagulants and transfusion have been tried, but remain unproven (3, 5) .
Several studies in non-sickle cell disease patients demonstrate therapeutic benefits of L-arginine therapy for pulmonary hypertension (6, 7) . Low plasma L-arginine concentrations have been discovered in infants with persistent pulmonary hypertension of the newborn (8) correlating with low nitric oxide metabolite levels (9) . L-arginine infusion has decreased pulmonary vascular resistance and improved blood oxygenation in infants with this disease process (10) . L-arginine supplementation also improves pulmonary artery pressures and hemodynamics in patients with primary and secondary pulmonary hypertension, (7) and one recent study demonstrates these effects after only 1 week of therapy (6) .
Inhalation of nitric oxide also lowers pulmonary artery pressures in both adults and infants with pulmonary hypertension (11, 12) . Recent studies suggest that rapid scavenging of nitric oxide by cell-free hemoglobin, which is found in high concentrations under conditions of hemolysis, may limit nitric oxide bioavailability in sickle cell disease (13) , while inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin (14) . Several case reports have also demonstrated significant improvement in pulmonary hypertension in children with acute chest syndrome after inhaled nitric oxide therapy (15, 16) .
Recent studies found that oral L-arginine normalizes red blood cell density and induces Gardos channel inhibition in sickle cell transgenic mice (17) . There is otherwise limited information available on the impact of L-arginine supplementation in sickle cell disease (18) .
However, improvement in pulmonary artery pressures has been described after treatment with arginine-butyrate in patients with sickle cell disease and pulmonary hypertension who were on hydroxyurea therapy. (19) L-arginine is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis (20) (21) (22) . Since nitric oxide generation is increased by hydroxyurea (23) (24) (25) (26) , treatment with hydroxyurea may deplete arginine stores even further. Therefore, it is possible that the arginine component of argininebutyrate may possess therapeutic properties, by replenishing the deficient substrate for nitric oxide production.
There is growing evidence that pulmonary hypertension is a disease process that involves altered arginine metabolism or decreased bioavailability. Arginase, an enzyme that converts L-arginine to ornithine and urea (27, 28) , may limit nitric oxide bioavailability in sickle cell disease through increased utilization of its substrate. Since arginine supplementation improves pulmonary artery pressures in non-sickle cell patients with pulmonary hypertension, (6, 7, 10) arginine may also be therapeutic for sickle cell disease patients with pulmonary hypertension by providing increased substrate for nitric oxide production.
Some results of this study have been previously reported in abstract form (29) (30) (31) (32) .
MATERIALS AND METHODS (word count: 486)
Patients. Ten sickle cell disease patients with documented pulmonary hypertension at steadystate were enrolled in the study. All known patients with pulmonary hypertension receiving care at the Northern California Comprehensive Sickle Cell Center were approached for participation in this study. Patients with renal or liver dysfunction were not eligible for enrollment. Eight patients were homozygous for hemoglobin S, one patient had hemoglobin type SC, and one patient had hemoglobin S β-thalassemia. The mean age of patients was 32.7±15 years with a range of 13 to 63 years. There were four women enrolled. Although one patient was determined to be non-compliant with taking the oral L-arginine supplements, he was still included in statistical analysis based on the intention-to-treat. Compliance was determined by a statistically Tricuspid regurgitant jet velocity was measured using both the parasternal long axis and four chamber view in order to confirm a concurrent value. Estimated pulmonary artery systolic pressures (mm Hg) based on changes in mean tricuspid regurgitant jet velocity were compared before and after treatment with oral L-arginine. Results are expressed as means±SD. The paired Student's t-test and one-way analysis of variance for repeated measures was used to evaluate for significant differences. A p value < 0.05 was considered statistically significant (35) .
Sample Size Calculation. Assuming a type one error rate = 5%, a within-group pulmonary artery systolic pressure standard deviation = 14, and a pre-post pulmonary artery systolic pressure correlation = 0.80, a matched pair t-test design with a sample size n = 10 would have 90% power to detect a mean change = 9.1 (e.g. approximately a 15% decrease in pulmonary artery systolic pressure).
RESULTS

Outcome measures pre and post L-arginine therapy
Echocardiography. Oral L-arginine supplementation significantly reduced pulmonary artery systolic pressure by a mean of 15.2% (63.9±13 to 54.2±12 mmHg, p=0.002) after five days of therapy ( Figure 1 ). One patient was determined to be non-compliant based on plasma L-arginine concentration at the end of the study (61.5 µM at Day 0 vs. 44.9µM Day 6). He was the only patient found to not show an improvement in pulmonary hypertension by echocardiogram.
The tricuspid regurgitant jet velocity from echocardiograms obtained > two months prior to study enrollment demonstrated stable estimated pulmonary artery systolic pressures in five patients, and worsening pulmonary hypertension in two patients. Results were unavailable from outside hospitals in three patients. Follow-up echocardiography was obtained at ≥ one month after arginine therapy in the nine compliant patients, with mixed results (Table 1 ). The noncompliant patient was lost to follow-up. Four patients reverted to their previous baseline pulmonary artery systolic pressures, four patients exhibited persistent improvement, and one patient demonstrated a worsening of pulmonary hypertension (echocardiography done while admitted for acute chest syndrome). Two of the patients demonstrating persistent improvement had also been started on transfusion therapy due to the severity of their disease, and one of these two patients had continued arginine therapy (at a dose of 0.1 gm/kg BID).
Amino Acid levels. Plasma L-arginine levels were low in patients with pulmonary hypertension compared to normal controls (50.8±19 vs. 114±27µM, p<0.0001), but similar to levels found in sickle cell patients at steady-state who did not have pulmonary hypertension (18, 20) . Ornithine levels were similar in both groups (53.4±13 vs. 57.0±20µM, pulmonary hypertension vs. normal controls respectively), however the arginine-to-ornithine ratio was significantly lower in patients with pulmonary hypertension (0.95±0.3 vs. 2.0±0.6, p<0.0001), probably reflecting increased arginase activity and decreased arginine bioavailability. Both L-arginine and ornithine concentrations increased significantly after five days of oral L-arginine supplementation (n=10, p<0.05, Figure 2 ).
Arginase activity. Arginase converts L-arginine to ornithine and urea ( Figure 3 ). Arginase activity in serum trended higher in sickle cell patients with pulmonary hypertension compared to normal controls, but did not reach statistical significance in this limited sample population (0.82±0.6 vs. 0.43±0.2µmol/ml/h, p=0.07). Of interest, the patients with the two highest levels of arginase activity (1.22 and 2.46µmol/ml/h) have died within one year of enrollment.
Other Effects. Arginine catabolism generates urea, which is excreted by the kidneys. Similar to the effects of a large protein load, high doses of L-arginine may cause a transient increase in blood urea nitrogen levels, and adequate hydration is necessary to avoid adverse effects to the kidneys. Liver function tests and renal function were followed with no significant changes noted. Commonly described side effects of oral arginine are associated with the gastrointestinal tract, including cramping and diarrhea (36) . Arginine supplementation was well tolerated and no adverse effects were reported.
A statistically significant increase in methemoglobin occurred (0.55±0.4 vs. 1.10±0.3, p<0.05). Although this change is not clinically relevant, it suggests an increase in nitric oxide production. Venous oxygen saturation measured by co-oximetry (37) increased from 56.8±18 to 76.4±9% after L-arginine supplementation (n=6; p=0.066). The single patient to demonstrate a decrease in venous oxygen saturation also experienced a decrease in his blood pressure. This patient had a history of hypertension treated with enalapril. His blood pressure normalized on Larginine therapy, necessitating a temporary discontinuation of enalapril while on study.
Otherwise, vital signs including blood pressure remained stable in all other patients. One patient described subjective improvement in a chronic leg ulcer after treatment with arginine, and two patients described improved exercise tolerance and energy level after therapy.
DISCUSSION
This is the only study to date that evaluates a potential new therapy for secondary pulmonary hypertension associated with sickle cell disease. As an increasingly recognized pulmonary complication of adulthood (2, 4, 38) , our study demonstrates that children are also affected. We currently have a 20% mortality rate within two years of the study's conclusion, consistent with the shortened survival described for this disease process (2, 4) . With a mean reduction in pulmonary artery systolic pressures of 15.2%, our results are consistent with previously reported experiences with arginine supplementation for pulmonary hypertension in non-sickle cell disease patients (6, 7, 10) . We also describe a new model of pathophysiology involving increased arginase activity that limits both arginine and nitric oxide bioavailability.
Endothelial dysfunction may contribute to the pathogenesis of pulmonary hypertension through impaired production of nitric oxide (7, (39) (40) (41) . It is likely that arginine's effects are linked to nitric oxide generation. Nitric oxide metabolism is altered during acute chest syndrome (42), a common pulmonary complication of sickle cell disease (43) associated with low plasma arginine (20) and nitric oxide metabolite levels (20, 44) , that is also often accompanied by pulmonary hypertension. Reported benefits of inhaled nitric oxide for acute chest syndrome (15, 16) suggest that nitric oxide-based therapies may be useful (45) . L-Arginine may be a safer and more easily administered alternative to inhaled nitric oxide gas.
Plasma levels of endothelin-1, the most potent endothelial-derived vasoconstrictor (46, 47) , are elevated in patients with sickle cell disease (48) and may contribute to the development of acute chest syndrome (49) and pulmonary hypertension (50, 51) . Nitric oxide directly inhibits endothelin-1 production and release (46) . L-Arginine also decreases circulating plasma endothelin-1 levels (52, 53), and is likely an added benefit for pulmonary hypertension.
Conditions of decreased nitric oxide bioavailability may allow for the upregulation of adhesion molecules (13, 54) and endothelin-1 (55), leading to a clinical scenario of pulmonary hypertension in the susceptible patient. It is possible that genetics plays a role in this susceptibility, as low exhaled nitric oxide and a polymorphism in the nitric oxide synthase gene have been linked to acute chest syndrome (56).
The rationale for arginine therapy has been questioned, since the low K m of nitric oxide synthase for L-arginine (< 10µM) (57) should prohibit arginine concentration from becoming rate limiting, even when circulating levels are below normal (20, 58, 59 ). However, rates of nitric oxide production vary according to extracellular arginine concentration, even when intracellular arginine levels are in apparent excess, a phenomenon termed the "arginine paradox" (60) . The mechanisms of this paradox are undefined, but likely involve decreased substrate bioavailability and attenuated nitric oxide synthesis, compounded by increased nitric oxide consumption. It has recently been recognized that scavenging of nitric oxide by elevated cellfree hemoglobin is a mechanism by which nitric oxide bioavailability is limited in sickle cell disease (13) . This, in turn, could lead to increased arginine metabolism in a compensatory attempt to produce more nitric oxide, thereby depleting arginine stores further during times of hemolysis, a hallmark of sickle cell crisis. Also, nitric oxide synthase will produce superoxide in lieu of nitric oxide when arginine concentration is low (61) . Superoxide, already increased in sickle cell disease (62) and augmented further by circulating xanthine oxidase (63) will consume nitric oxide to form the potent oxidant, peroxynitrite (64) , further limiting nitric oxide bioavailability and possibly inducing cellular injury. Studies in transgenic sickle cell mice demonstrate that nitric oxide synthase activity is paradoxically increased (65, 66) , again suggesting in a futile compensatory attempt to replenish the deficient nitric oxide pool. Our data supports a mechanism whereby arginase activity would further limit arginine bioavailability and translate to decreased nitric oxide production.
Found predominantly in the liver and kidneys, arginase is also present in human red blood cells (67) and it can be induced in many cell types by a variety of cytokines and inflammatory stimuli (27, 28, 68) . Arginase activity may play a regulatory role in nitric oxide production, as it can limit availability of arginine for nitric oxide synthase (69) (Figure 3 ). Under pathologic conditions of elevated arginase activity, a higher than expected increase in arginine concentration may be necessary in order to induce a therapeutic effect. Elevated plasma arginase activity has been described in patients with sickle cell disease (59), but its role in pulmonary hypertension has not been previously explored. We observed that oral arginine supplementation significantly increased ornithine levels. Plasma arginase activity trended higher in patients with pulmonary hypertension compared to non-sickle cell normal controls, and the two patients with the highest levels have died within one year of enrollment. Elevated arginase activity may therefore be a marker of greater disease severity or end-organ damage. Arginase activity present in the serum of patients probably does not accurately reflect whole body arginase activity, since the arginases are intracellular enzymes that appear in the circulation after cell damage or cell death. The arginine-to-ornithine ratio may therefore be a superior reflection of total arginase activity. This ratio would also be helpful in evaluating arginine bioavailability, as ornithine competes with L-arginine for cellular uptake. The arginine-to-ornithine ratio was significantly lower in sickle cell patients with pulmonary hypertension compared to normal controls, suggesting a role for arginase in the "arginine paradox".
None of our patients underwent a cardiac catheterization, the gold standard for evaluation of pulmonary hypertension. This may be considered a major limitation in our study. However, echocardiography is a noninvasive measurement shown to reliably predict pulmonary artery pressures in patients with chronic heart failure (70, 71) , and those with pulmonary hypertension awaiting lung transplant, correlating with results of cardiac catheterization (72). Gladwin and colleagues recently confirmed this strong correlation between the 2 techniques (r=0.98; p<0.001)
in patients with sickle cell disease and pulmonary hypertension (38) . Although the sample size of our study population was relatively small, we were sufficiently powered to detect a difference in pulmonary pressures ≥ 15% in 10 patients. Eligible patients who had not yet developed renal or liver dysfunction were scarce. This implies that the diagnosis is often being determined late in the clinical course. It is possible that patients develop pulmonary hypertension as a manifestation of more severe disease; however, a broader screening of asymptomatic patients by echocardiography may reveal occult pulmonary hypertension preceding complications, thus allowing for earlier intervention (73).
In conclusion, arginine is a well tolerated, non-toxic nutritional supplement with few side effects (52, (74) (75) (76) (77) (78) (79) (80) (81) . With the high mortality rate and limited treatment options available for these patients, L-arginine supplementation a promising new therapy that warrants further investigation.
In addition, this data suggests that elevated arginase activity may contribute to the pathogenesis of pulmonary hypertension in sickle cell disease. The correlation of disease severity and the arginine-to-ornithine ratio should also be explored, as it may represent an easily measured, objective marker that could identify patients at risk and allow for earlier intervention. Blinded, controlled studies with longer duration of therapy are needed to extend our preliminary findings and determine the safety and efficacy of arginine therapy in sickle cell disease. instead of generating nitric oxide (61, 62) . Nitric oxide reacts rapidly with superoxide to form reactive nitric oxide species (RNOS) that could lead to oxidative stress and cellular damage (64) .
Pathological conditions of increased arginase activity could have a negative impact on nitric oxide bioavailability. 
